The COVID-19 Delta variant is raging through the US putting patients on hemodialysis (HD) at higher risk for infection. John Milad, CEO of Quanta Dialysis Technologies discusses how this time can be used as a catalyst for positive change in the care of HD patients through accessible remote care and why innovation is needed now to bring a positive impact to the healthcare system and patients.
John is CEO, founding Board Member and an original investor in Quanta Dialysis Technologies.
He had the initial vision that the industrial technology concept of a cartridge-based fluid management system could be transformed into a disruptive medical product addressing the $82B dialysis market, which has suffered from a lack of innovation for over 30 years. Under John’s leadership, Quanta has developed SC+ to address unmet market needs and built the capabilities required to commercialize and scale the business.
John has over 20 years of extensive experience building and growing successful healthcare companies as an executive manager, board member, private equity investor and corporate financier. Prior to his role as CEO of Quanta, John was an Investment Director at NBGI ventures, where both as a board member and investor, he was closely involved with a range of innovative medical technology companies in Europe and the US. Before that, John headed up Finance and Business Development at Nitec Pharma AG (now Horizon Pharma), which was a Swiss, venture-backed speciality pharma company. He has also held various senior positions at healthcare investment companies including Atlas Venture and Nomura. John has also served as a Board Director at Cellnovo Limited (which successfully IPOed), BoneSupport (which successfully IPOed) and Symetis SA (which was sold to Boston Scientific for $450m). John was recognized by The Sunday Times 2019 Maserati award as one of the UK’s top 100 game changing innovators and entrepreneurs in the UK. He holds a B.A. in Political Science from the University of Chicago.